Bicyclic Hydroxy-1H-pyrrolopyridine-trione Containing HIV-1 Integrase Inhibitors

HIV-1 integrase (IN) is a validated therapeutic target for the treatment of AIDS. However, the emergence of resistance to Raltegravir, the sole marketed FDA-approved IN inhibitor, emphasizes the need to develop second-generation inhibitors that retain efficacy against clinically-relevant IN mutants....

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Chem Biol Drug Des
Autori principali: Zhao, Xue Zhi, Maddali, Kasthuraiah, Metifiot, Mathieu, Smith, Steven J., Vu, B. Christie, Marchand, Christophe, Hughes, Stephen H., Pommier, Yves, Burke, Terrence R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2011
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6385889/
https://ncbi.nlm.nih.gov/pubmed/22107736
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1747-0285.2011.01270.x
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi